• SPX
  • $5,794.85
  • 0.76 %
  • $43.72
  • DJI
  • $42,512.00
  • 1.03 %
  • $431.63
  • N225
  • $39,277.96
  • 0.87 %
  • $340.42
  • FTSE
  • $8,243.74
  • 0.65 %
  • $53.13
  • IXIC
  • $18,297.11
  • 0.63 %
  • $114.19
BioXcel Therapeutics, Inc. (BTAI) Stock Price, News & Analysis

BioXcel Therapeutics, Inc. (BTAI) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.54

-$0.01

(-2.31%)

Day's range
$0.53
Day's range
$0.57
50-day range
$0.505
Day's range
$1.14
  • Country: US
  • ISIN: US09075P1057
52 wk range
$0.51
Day's range
$5.62
  • CEO: Dr. Vimal D. Mehta Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -17.76
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (BTAI)
  • Company BioXcel Therapeutics, Inc.
  • Price $0.54
  • Changes Percentage (-2.31%)
  • Change -$0.01
  • Day Low $0.53
  • Day High $0.57
  • Year High $5.62

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/12/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $10.00
  • High Stock Price Target $25.00
  • Low Stock Price Target $1.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$5.18
  • Trailing P/E Ratio -0.27
  • Forward P/E Ratio -0.27
  • P/E Growth -0.27
  • Net Income $-179,053,000

Income Statement

Quarterly

Annual

Latest News of BTAI

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.